focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
lets hope it works well & the cost comes right down.
in fact, it is the time of year perhaps that we should pray for that
GLA
I didn't think of it like that.
Lets say they save doing 300 tests at 1 dose & a dose has sale price of $3k = $900,000 but
instead of having to do 300 tests at 2 doses they have to do 305 = (15,000)
& if the treatment was approved, it would be approved for doses of 2 syringes for ever more not 1 syringe, there would be more pressure on scaling up production because the market would be much larger. If they expected a 50:50 split between 1 & 2 syringe treatments out of 100,000 per month, they'll have to produce 25,000 more per month & earn not $3,000,000,000pm but $75,000,000pm more if the health authorities accept $6,000 per 2 dose treatment.
Lets hope for good test results
y, & who knows what other urgent issues the FDA might have on their plate. I am glad they seem to have a priority for this and so relieved there isn't some unintended mishap in administration that impedes a treatment for a horrible condition.
I am so relieved. If this treatment can help people who suffer cytokine storm, it really should be a priority to get it to them with least delay to reduce human tragedy.
I am glad the FDA & the other public health bodies seem to be working effectively with our company towards meeting a grave public need in the way they should without unintended delays or miscommunications.
Phew.
It is a French company, Novacyt SA (not PLC) first listed on the Euronext exchange in Paris (under a French code of disclosure requirements and French corporate governance) that chose to list also in the UK. 70% traded there 30% in UK.
Don't know the history, other than the French company bought a UK entity that then expanded by acquisition of other UK entities. There are some positives in being listed under French regs like they can less easily issue a placing at discount to an II & some negatives, like lack of requirement to disclose significant shareholdings in YE accounts or as holdings move between the bands set by the City Code on the London Stock Exchange.
Perhaps they have been able not to hold much stock that is their by invoicing sales to customers in advance of it being produced but only issuing demands for payment as supply is called off the contract under whatever terms they agree (eg when it is shipped or delivered or perhaps even as soon as it has been made!)
You can imagine that may have happened with vaccines purchased by governments - one big contract for the x million supplied on a schedule (subject to specified dependencies like regulatory approval) funded by a stream of demands for payment in line with terms agreed for calling stock off the sale (which could be when an order is placed, delivered or some other variant). Are those vaccine producers going to have a working capital problem? All there stuff sold before it was made!
I agree any changes in wins & post covid prospects mean rerating.
We should recall the context Numis issued their guide in. They had recently been appointed as joint broker, 70% of shares trade in France and the SP had been at the mercy of shorters & mishap for 6 months under 300p & 250p at times.
It seemed to me at least that Numis picked a basis that was undeniable - i.e. not the most likely or upbeat but one that could not be denied to show the share price should upgrade to what was 100% undeniable & then on to whatever may develop in a fast moving situation.
Matml74
Did you read this statement in the RNS issued by GDR today? "David Budd, CEO of genedrive plc, said: "genedrive submitted its application to the FDA in May of this year but owing to the volume of applications received we are still waiting for EUA review." What they have been telling their shareholders about when they expect to approval! They might well use a word like "imminent" because of their sense of urgency that can not influence their timescale.
I had confidence is SNG's guidance until now that "urgent" has meant 5 months before starting Phase 3. You compare this with organising other Phase 3 trials but it is set in a pandemic. It was officially designated a National Priority as a label to highlight time, volume and mass public health pressure not quite the same as settings for treatments. I have been naive about what that might mean.
So, I hope you can see more sense in my point.
It feels like we are in for a wait to see when the Phase 3 will start. It may not be in influence of SNG, who may well have done very well as you say. It will leave us the opportunity to buy on a falling share price the longer it goes on, rather like at GDR (now 44p!) & rue naivety over what urgency meant to all involved. Perhaps vaccines are more urgent to the FDA et al.
Lets hope for news & relax.
Does anyone get the feeling the trial has been put on hold until the vaccine has been rolled out or something else has happened?
I thought it was urgent back in July but perhaps they are waiting for Christmas now.
Isn't it logical that new strains are more infectious. Would they survive if they weren't?
I think the more virulent strains might spread faster, because, that is what they do. Are they any more or less likely to mutate? Probably, not per se, but since there are more of them, their mutation is also at a faster rate.
Answer - develop treatment capability, by, for example starting SNG's Phase 3 test.
Does anyone else wonder about the coincidence in timing of Han****'s announcement to Parliament concerning a new strain and Novacyt's RNS yesterday concerning their work on new strains?
I know NCYT has referred to other strains before but it was as though their RNS had been coordinated with the statement in Parliament or perhaps vice versa.
Who thinks a protocol may be in play concerning the issue of information?
Agree with NewSid, nice someone looks at figures.
Other contributors argue CPI is massively undervalued, how can it be at this levels, it must double & treble, multibag and the catalyst for smashing resistance levels (upwards) is the ESS sale now (presumably set back by brexit uncertainty) but without a look at P&L performance & plans, debt or cash.
IMO SP depends on confidence in the plan to build back a dividend stream & without one of the most significant stand alone profit streams now. Agree 2023 earliest.
At least 2020 will show a profit before tax on a non adjusted basis from this gain & 50m of loan from Pension scheme against ESS will have been paid back. Lets hope the central overheads, exceptional advice, restructuring, amortisation, impairment and development cost write offs have been controlled this year presumably by the exiting FD.
Hope this goes up. Lets hope an II increases their stake without waiting for YE audited figures.
This is a French company! lol
Isn't it strange the scrutiny AVCT seems to be put through compared to what we knew about Innova before they were awarded the contract that it now appears their test has done poorly in.
74 days is an interesting find, thanks bobbybullet, well done
I had day 60 flagged & took the fall in SP this week as due to absence of announcement (meaning no fast track news) as presumably others have done when perhaps gives opportunity to top up at a lower SP.
GLA on announcement when it comes
On reflection, my bigger risk may be making £100k when the SP rocketing but me holding as it holds eye watering more potential that is recognised as being a National Priority of urgent need only to find the £100k has disappeared 5 months later and its shareholders struggling to reason when the next step will start.
perhaps we should ask how many of us top sliced without then ploughing the slice back in as SNG dropped back
I'd probably sell an amount - say enough to cover my cost + 20% & let the risk run.
Rational - losses hurt more than gains (post tax) change life.
I'd like to win big without the risk of feeling a loss so I'd give up something as psychological self protection insurance.
some big buys show on L2